Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance
Johnston, Elizabeth Winters, Mark A. Rhee, Soo-Yon Merigan, Thomas C. Schiffer, Celia A. Shafer, Robert W.
Johnston, Elizabeth
Winters, Mark A.
Rhee, Soo-Yon
Merigan, Thomas C.
Schiffer, Celia A.
Shafer, Robert W.
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Journal Article
Publication Date
2004-11-25
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with multidrug resistance and a compensatory increase in replication capacity.
Source
Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8. Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1128/AAC.48.12.4864-4868.2004
Permanent Link to this Item
PubMed ID
15561868